Methods for affecting body composition

• US 7,399,744 B2
• Filed: 05/20/2004
• Issued: 07/15/2008
• Est. Priority Date: 03/04/2004
• Status: Expired due to Fees

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Roth, Jonathan David, Mack, Christine Marie
• Primary Examiner(s): Tsang; Cecilia
• Assistant Examiner(s): Heard; Thomas S.
• Application Number:
  US10/851,574
• Publication Number:
  US 20050197287A1
• Time in Patent Office: 1,517 Days
• Field of Search: None
• US Class Current: 514/4.8
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.

Claims

1. A method for reducing body fat or body fat gain in a subject, while maintaining or increasing lean body mass, comprising administering to the subject an amylin agonist comprising the structure of SEQ ID NO:

5;

thereby, reducing body fat or body fat gain while maintaining or increasing lean body mass.

2. The method of claim 1 wherein the subject is a mammal.

3. The method of claim 2 wherein the mammal is human.

4. The method of claim 3 wherein the human is overweight or obese.

5. The method of claim 1 wherein the amylin agonist is administered parentally.

6. The method of claim 1 wherein the body fat and lean body mass is percent body fat and percent lean body mass, respectively.

7. The method of claim 1 further comprising dieting.